Protocol: Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations (30 June, 2021)
Takayuki Kondo , Haruhiko Banno , Taro Okunomiya , Yoko Amino , Kayoko Endo , Akiyoshi Nakakura , Ryuji Uozumi , Akemi Kinoshita , Harue Tada , Satoshi Morita , Hidehiro Ishikawa , Akihiro Shindo , Ken Yasuda , Yosuke Taruno , Takakuni Maki , Takashi Suehiro , Kohji Mori , Manabu Ikeda , Koji Fujita , Yuishin Izumi , Kazutomi Kanemaru , Kenji Ishii , Kazue Shigenobu , Yumiko Kutoku , Yoshihide Sunada , Shinobu Kawakatsu , Shunji Shiota , Toshifumi Watanabe , Osamu Uchikawa , Ryosuke Takahashi , Hidekazu Tomimoto , Haruhisa Inoue